A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value.
A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value. Focusing on non-small cell lung cancer (NSCLC), the brief used the IVI-NSCLC model, an open-source simulation model that assesses the costs, benefits, and risks of sequences of treatment for EGFR-mutated disease. The model also includes an experimental module for calculating the value of hope, which has been suggested as one of the elements to augment conventional cost-effectiveness analysis.
Costs and outcomes for 2 possible treatment sequences were determined and the value of hope was added to the quality-adjusted life years (QALYs) by estimating the QALYs a patient would need to obtain to be indifferent toward the 2 sequences of treatment.
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen